Difference between revisions of "Duloxetine-mirtazapine"

From Psychiatrienet
Jump to: navigation, search
Line 9: Line 9:
 
* '''Day 8:''' start mirtazapine in a normal dosage of 15-30 mg/day.
 
* '''Day 8:''' start mirtazapine in a normal dosage of 15-30 mg/day.
 
* '''Day 15:''' if necessary increase mirtazapine.  
 
* '''Day 15:''' if necessary increase mirtazapine.  
 +
 +
|info={{review}}
 
}}
 
}}

Revision as of 14:49, 2 November 2015

Duloxetine
Type Antidepressant
Group SNRI
links
Medscape Duloxetine
PubChem 60835
PubMed Duloxetine
Kompas (Dutch) Duloxetine
Wikipedia Duloxetine
Mirtazapine
Type Antidepressant
Group other
links
Medscape Mirtazapine
PubChem 4205
PubMed Mirtazapine
Kompas (Dutch) Mirtazapine
Wikipedia Mirtazapine

Switch medication from duloxetine to mirtazapine.[1] [2]

Nietinrijdenbord.png Stop duloxetine
  • Before day 1: gradually reduce dosage of duloxetine to a maximum of 60 mg/ day.
  • Day 1: reduce a dosage of 60 mg/day to 30 mg/day.
  • Day 8: stop administration of duloxetine.
Eenrichtingbord.png Start mirtazapine
  • Day 8: start mirtazapine in a normal dosage of 15-30 mg/day.
  • Day 15: if necessary increase mirtazapine.
Infobord.png More information
  • This switch is currently being reviewed.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.